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cultured with DAPT exhibited a less pronounced fall of mRNA
and protein level of type II collagen and aggrecan, and a minor
increase of type I collagen mRNA. In order to further confirm the
participation of Notch1 in the dedifferentiating process of iMACs,
we transiently transfected the cultured cells with an expression
plasmid encoding a constitutively active form of Notch 1 receptor
(DE form) which is constitutively cleaved by the γ-secretase,
releasing the transcriptionally active nuclear form of Notch, ICv.
After 24 hours of transfection we observed a strong diminution of
type II collagen amount, detected by western blot, whereas the
Notch1 full length construction as well as the empty vector had
no detectable effect. This diminution was abolished in presence
of the γ-secretase inhibitor DAPT (2,3μM).
Conclusions: These data show that the Notch pathway is critical
in the dedifferentiation process of articular chondrocytes. We
suggest that modulating the Notch pathway could be a novel
approach in the treatment of OA.
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Purpose: Alterations in chondrocyte differentiation, including
chondrocyte hypertrophy, promote dysregulated articular carti-
lage matrix repair and tissue failure in aging and osteoarthritis
(OA). IL-8 and TNFα induce chondrocyte hypertrophy, dependent
on both release of ligands of receptor for advanced glycation
endproducts (RAGE) and expression of the protein crosslinking
enzyme transglutaminase 2 (TG2). S100/calgranulins are proto-
typical RAGE ligands. S100A11 release, markedly upregulated in
human OA chondrocytes in situ, is induced by IL-8 and TNFα in
vitro. S100A11 is crosslinked by TG2-catalyzed transamidation to
change conformation and multimerize, with potential for altered
signaling through the calgranulin receptors RAGE and CD36.
Hence, we tested the hypothesis that TG2 post-translationally
modifies S100A11 released by chondrocytes, triggering articular
chondrocyte maturation to hypertrophy.
Methods: We studied not only human articular chondrocytes
but also RAGE knockout, TG2 knockout, and congenic wild
type mouse femoral head articular cartilage explants. Adapting
methods of Salvat et al (OA Cartilage 13:243, 2005), we also
isolated immature murine articular chondrocytes confirmed to
uniquely express type II collagen and aggrecan. We generated
TG2 transamidation site point mutants (K3L, Q102N, and both) of
human S100A11 and as a control a K52R S100A11 site mutant.
We also made single and double mutants for human TG2 GTP
binding (K173L) and transamidation catalytic (C277G) sites.
Results: RAGE knockout chondrocytes and femoral head carti-
lage explants retained the capacity for IL-1-induced NO and GAG
release, ADAMts4 and 5 expression, and decreased proteogly-
cans (PG) synthesis. In contrast, we confirmed that IL-8 and
TNFα required RAGE to induce type X collagen in chondrocytes
(J. Immunol. 175:12, 2005), and TNFα-induced GAG release
was blunted in RAGE knockout cartilage explants. Nanomolar
S100A11 failed to induce type X collagen and other markers
of chondrocyte hypertrophy in both RAGE and TG2 knockout
mouse chondrocytes and in human chondrocytes in which TG2
was knocked down by RNAi. Conversely, nanomolar exogenous
TG2 markedly accelerated chondrocyte hypertrophy in response
to recombinant S100A11, an effect abrogated by the TG2 C277G
but not K173L mutation. The K3R/Q102N S100A11 mutation
but not the K52R S100A11 mutation removed the capacity of
S100A11 to induce chondrocyte hypertrophy. Wild type but not
K3R/Q102N mutant S100A11 stimulated a 69% increase in GAG
release in wild type mouse femoral head cartilage explants
(P<0.05). Wild type S100A11 also failed to induce GAG release
in either RAGE or TG2 knockout explants. Last, wild type but
not K3R/Q102N mutant S100A11 induced decreased PG syn-
thesis in cultured chondrocytes. In contrast, wild type S100A11
induced 80-120% increase in PG synthesis in TG2 knockout
chondrocytes compared to wild type (P<0.05).
Conclusions: TG2-catalyzed transamidation of K3 and Q102
residues transforms latent S100A11 calgranulin to a conforma-
tional state in which S100A11 induces hypertrophic differenti-
ation, GAG release, and decreased PG synthesis. Conversely,
S100A11 fails to do so in the absence of RAGE or TG2(or the
capacity to be transamidated and crosslinked by TG2), condi-
tions under which S100A11 actually is anabolic as evidenced
by PG synthesis. Our results suggest a novel model by which
chondrocyte hypertrophy and a matrix catabolic program in OA
cartilage are switched on by pericellular TG2-induced conforma-
tional change in cytokine-inducible secreted calgranulins.
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Purpose: The aim of this study was to determine whether intra-
articularly delivered TIMP-3 protects cartilage in a rat meniscal
tear model of osteoarthritis. TIMP-3, a protein of 24 kD that
binds to extracellular matrix, is a potent inhibitor of the metal-
loproteases that degrade aggrecan and type II collagen. It also
inhibits TACE, the major enzyme that generates the soluble form
of TNF. The protein consists of two discrete domains, and the
inhibitory function is carried out by the N-domain. The N-domain
has been shown to block IL-1-driven glycosaminoglycan (GAG)
release in cartilage explants.
Methods: Two forms of TIMP-3 were produced: His-tagged full-
length was made in CHO cells, while the N-domain was made in
E. coli and refolded. Both forms were tested for efficacy against
metalloproteases in vitro, against TNF release in cell culture, and
against GAG release in bovine nasal cartilage explants. They
were then tested in a model of osteoarthritis in which symptoms
are induced by cutting the meniscus in knees of male Lewis rats.
The test proteins, rat serum albumin, or vehicle were injected
intra-articularly every other day for 3 weeks, starting one day
prior to the surgery. The volume injected was 60 ul; the amount
of protein was 100 ug for full-length TIMP-3 and albumin, 62 ug
for the N-domain. At the end of the 3-weeks, joints were fixed,
embedded, sectioned and stained, and then analysis was carried
out for GAG content, cartilage width at various sites, osteophytes
and bone lesions.
Results: Full-length TIMP-3 inhibited MMP-13 by about 80%
at a ratio of 1:1, while the N-domain did so only at a 20-fold
higher concentration. However, the two forms were similarly
effective against other metalloproteases tested, and in blocking
TNF release from a mouse monocytic cell line (IC50 about 75
nM in the cell assay). Both forms blocked IL-1-induced GAG
release from bovine nasal cartilage, with IC50s of about 100
nM and 30 nM for full-length and N-domain, respectively. In the
rat meniscal tear model, both forms reduced symptoms, with the
most dramatic effects seen in the rats that received the full-length
protein: 94% reduction in significant tibial cartilage degeneration
width, 53% reduction in medial tibial osteophyte score, 67%
reduction in bone score, and 57% reduction in total joint score.
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Conclusions: We found that N-domain and full-length TIMP-3
are similarly effective in most in vitro and cell-based assays,
although full-length was more potent against MMP-13. The N-
domain was more effective in blocking IL-1-induced GAG release
from bovine nasal cartilage explants. Both forms, but most dra-
matically the full-length protein, inhibited cartilage degradation,
osteophyte growth and bone lesions in a rat meniscal tear model
of osteoarthritis. The greater efficacy seen with the full-length
form could be due to its greater potency against MMP-13.
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Purpose: BMP-2 has often been proposed as a good tool for
cartilage repair and as a strong stimulant of chondrogenesis.
Cells modified to overexpress BMP-2 and scaffolds coated with
BMP-2 have been placed into a cartilage defects for reparative
purposes. However, it is unknown what BMP-2 does on intact
cartilage that is present in the treated joints. To study the effect
of BMP-2 on intact cartilage in vivo, we overexpressed BMP-
2 in normal murine knee joints and evaluated the effects on
proteoglycan synthesis and degradation.
Methods: C57Bl/6 mice were injected intra-articularly with an
adenovirus overexpressing BMP-2. Mice were injected i.p. with
35SO2-4 24 hours before sacrifice. After 3, 7 and 21 days kneejoints were isolated for histology to perform Safranin O/Fast
Green staining and autoradiography to assess anabolic effects
of BMP-2. Immunohistochemical staining of the aggrecan neo-
epitopes VDIPEN and NITEGE was carried out to investigate
GAG degradation. Histological quantification of staining in patel-
lar and tibial cartilage was performed with a computerized imag-
ing system. In addition, patellar and tibial cartilage were isolated
for measurement of proteoglycan (PG) synthesis by means of
35SO2-4 incorporation or RNA isolation for quantitative PCR.
Results: BMP-2 overexpression resulted in altered chondrocyte
appearance, which appeared to be larger than chondrocytes in
control cartilage. Furthermore, BMP-2 stimulated PG-synthesis
in patellar cartilage significantly on all days (up to two fold) and
in the tibia on day 21. Stimulation was less prominent in tib-
ial cartilage than in patellar cartilage. On mRNA level collagen
type II expression had increased on all days in the patella with
the highest expression on day 7 (17-fold) Aggrecan expression
showed the same pattern with a a 13-fold increase on day 7.
On the tibia collagen type II expression had increased 12-fold
on day 7 and 14-fold on day 21 and aggrecan expression was
elevated 15-fold on day 7 and 12-fold on day 21.In addition
to stimulation of extracellular matrix production, BMP-2 overex-
pression also resulted in MMP- as well as ADAMTS-mediated
cartilage degradation. VDIPEN staining (indicating MMP activity)
was elevated upon BMP2 stimulation on day 3 on tibial cartilage
and on day 3 and 7 in patellar cartilage, but no longer by day
21. NITEGE staining (indicating aggrecanase activity) was not
found on day 3, but this is likely due to elevated MMP-activity
cleaving off the NITEGE epitope. On day 7 NITEGE staining had
increased 2-fold in the lateral tibial condyle and 3,5 fold in patel-
lar cartilage, which was still increased 2-fold on day 21. On RNA
levels we found elevated MMP3 expression on both tibia and
patella, and elevated ADAMTS4 expression in the patella. BMP-
2 overexpression did not result in detectable cartilage damage in
Safranin O/Fast Green stained sections.
Fig. 1
Conclusions: Adenoviral overexpression of BMP-2 shows that
BMP-2 is able to elevate proteoglycan synthesis in cartilage
and stimulates collagen type II and aggrecan mRNA expression.
At the same time increased catabolic activity was observed
indicated by elevation of VDIPEN and NITEGE neo-epitopes.
These data show that BMP2 not only boosts matrix synthesis
in normal cartilage but that BMP-2 increases matrix turnover.
Increased matrix turnover might be functional to replace matrix
molecules in the repair of a damaged cartilage matrix.
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Purpose: IKKα and IKKβ are essential kinases for activating
NF-κB transcription factors that regulate cellular differentiation
and inflammation. Each IKK was targeted for knockdown (KD)
